Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.
Abigail Lewis
Advertisement
Articles by Abigail Lewis
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Upcoming 2026-2027 Vaccine Season: Deals, Data, and an FDA Vote
2
Orca-T Gains FDA Approval for Matched Donor Stem Cell Transplant
3
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
4
House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden
5